Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
Recruiting
Observational Study
Epidermolysis Bullosa Dystrophica
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Patients with recessive dystrophic epidermolysis bullosa (RDEB) suffer from acute and chronic post-bullous wounds along with impaired skin healing. These issues are attributed not only to mucocutaneous fragility and abnormal healing directly related to quantitative and/or qualitative constitutional abnormalities of collagen VII but also to a contingent cutaneous and systemic inflammatory component…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
EBDR patients :
* Patients aged 18 to 80 years old
* Clinically, histologically, and/or genetically confirmed intermediate, reversed or generalized, moderate to severe EBDR
Healthy controls :
* Adults aged 18 to 80 years old
* PBMC healthy donors: subjects who have donated bl…
Contacts